Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) have earned an average recommendation of “Buy” from the five ratings firms that are presently covering the stock, MarketBeat reports. Five equities research analysts have rated the stock with a buy recommendation. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $27.80.

CPRX has been the topic of several research reports. StockNews.com raised shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, June 7th. Oppenheimer reissued an “outperform” rating and issued a $29.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, June 6th. HC Wainwright reissued a “buy” rating and issued a $26.00 price target on shares of Catalyst Pharmaceuticals in a research report on Monday, June 3rd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $34.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, March 22nd.

Insiders Place Their Bets

In other Catalyst Pharmaceuticals news, insider Carmen Jeffrey Del sold 7,541 shares of the business’s stock in a transaction that occurred on Friday, June 7th. The shares were sold at an average price of $16.07, for a total value of $121,183.87. Following the completion of the transaction, the insider now owns 18,427 shares of the company’s stock, valued at approximately $296,121.89. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Catalyst Pharmaceuticals news, insider Carmen Jeffrey Del sold 7,541 shares of the business’s stock in a transaction that occurred on Friday, June 7th. The shares were sold at an average price of $16.07, for a total value of $121,183.87. Following the completion of the transaction, the insider now owns 18,427 shares of the company’s stock, valued at approximately $296,121.89. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Molly Harper sold 5,333 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $16.30, for a total transaction of $86,927.90. The disclosure for this sale can be found here. Insiders sold a total of 110,197 shares of company stock valued at $1,777,560 in the last quarter. Corporate insiders own 11.00% of the company’s stock.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the business. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Catalyst Pharmaceuticals by 12.5% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 18,028 shares of the biopharmaceutical company’s stock valued at $279,000 after purchasing an additional 2,002 shares in the last quarter. Juncture Wealth Strategies LLC boosted its stake in shares of Catalyst Pharmaceuticals by 2.3% in the 2nd quarter. Juncture Wealth Strategies LLC now owns 96,801 shares of the biopharmaceutical company’s stock valued at $1,499,000 after purchasing an additional 2,218 shares in the last quarter. Strategic Advocates LLC boosted its stake in shares of Catalyst Pharmaceuticals by 6.5% in the 2nd quarter. Strategic Advocates LLC now owns 14,142 shares of the biopharmaceutical company’s stock valued at $219,000 after purchasing an additional 864 shares in the last quarter. Richard P Slaughter Associates Inc purchased a new stake in shares of Catalyst Pharmaceuticals in the 2nd quarter valued at $2,513,000. Finally, Linden Thomas Advisory Services LLC boosted its stake in shares of Catalyst Pharmaceuticals by 27.4% in the 2nd quarter. Linden Thomas Advisory Services LLC now owns 21,326 shares of the biopharmaceutical company’s stock valued at $330,000 after purchasing an additional 4,583 shares in the last quarter. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX stock opened at $16.99 on Wednesday. The firm has a market cap of $2.01 billion, a price-to-earnings ratio of 31.46 and a beta of 0.71. Catalyst Pharmaceuticals has a 52 week low of $11.55 and a 52 week high of $17.50. The firm’s 50-day simple moving average is $15.80 and its two-hundred day simple moving average is $15.37.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported $0.31 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.31. Catalyst Pharmaceuticals had a net margin of 15.83% and a return on equity of 25.08%. The company had revenue of $98.51 million for the quarter, compared to analyst estimates of $97.24 million. Analysts forecast that Catalyst Pharmaceuticals will post 1.63 earnings per share for the current year.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.